Drug Development

All articles by Drug Development

Genentech, Nvidia ink strategic AI collaboration to boost drug development
Genentech, Nvidia ink strategic AI collaboration to boost drug development
Jack O'Brien
November 21, 2023
10:48 am

The acceleration of Genentech’s machine learning (ML) capabilities will take place on Nvidia’s DGX Cloud. This includes Nvidia BioNemo, which uses generative AI applications in drug discovery.

Sanofi, Teva collab on $1.5B deal for anti-TL1A therapy for IBD
Sanofi, Teva collab on $1.5B deal for anti-TL1A therapy for IBD
Jack O'Brien
October 4, 2023
10:18 am

On the commercialization front, Teva will lead in Europe, Israel and specified countries while Sanofi will take the helm in North America, Japan, certain parts of Asia and the rest of the world.

Sanofi goes oral route in Recludix deal to develop tailored I&I drugs
Sanofi goes oral route in Recludix deal to develop tailored I&I drugs
Marc Iskowitz
July 21, 2023
9:22 am

The Sanofi-Recludix deal is another sign that oral development programs against autoimmune disease targets are enjoying a bit of a moment.

Just-Evotec Biologics inks $74M orthopoxviruses contract with U.S. gov
Just-Evotec Biologics inks $74M orthopoxviruses contract with U.S. gov
Lecia Bushak
July 5, 2023
3:27 pm

By illuminating landmarks across the country, a campaign brought new visibility to a disease and a foundation.

Cyclerion deals 2 compounds to a spinoff firm
Cyclerion deals 2 compounds to a spinoff firm
Marc Iskowitz
May 15, 2023
3:37 pm

Following the transaction, the new company will be responsible for developing and commercializing zagociguat and CY3018.

Jazz exercises its option for rights to Zymeworks’ zanidatamab for $350M
Jazz exercises its option for rights to Zymeworks’ zanidatamab for $350M
Jack O'Brien
December 21, 2022
2:51 pm

Total payments to Zymeworks based on the success of zanidatamab could exceed $1.75 billion.

Novo Nordisk scoops up Ventus’ lead NLRP3 drug candidate for $70M
Novo Nordisk scoops up Ventus’ lead NLRP3 drug candidate for $70M
Jack O'Brien
September 29, 2022
3:46 pm

The deal includes potential milestones of up to $633 million as well as royalty payments and R&D funding.

Discovery Channels: In Watson’s wake, AI finds new life
Discovery Channels: In Watson’s wake, AI finds new life
John Newton
September 7, 2022
1:00 pm

Watson Health might have come up far short of expectations, but AI techniques remain poised to reinvent drug discovery.

Meet 5 next-gen drugs angling to restock the COVID-19 armamentarium
Meet 5 next-gen drugs angling to restock the COVID-19 armamentarium
Marc Iskowitz
February 25, 2022
3:06 pm

Analysts called these out as a group of emerging agents that could one day supplant our existing coronavirus therapies.

Did the market overreact to Biogen’s Alzheimer’s data?
Did the market overreact to Biogen’s Alzheimer’s data?
Lauren Evans
July 10, 2018
3:49 pm

Biogen’s recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.

  • From Our Partners